Previous close | 9.00 |
Open | 9.00 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 95.00 |
Expiry date | 2025-01-17 |
Day's range | 9.00 - 9.00 |
Contract range | N/A |
Volume | |
Open interest | N/A |
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
West Pharmaceutical's (WST) first-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.